
Mindstate Design Labs
Clinical-stage AI neuroengineering platform
San Francisco, United States · Founded 2021 · $37.2M raised
- Headquarters
- San Francisco, California
- Employees
- 1–10
- Founded
- 2021
- Website
- mindstate.design
- Total Funding
- $37.2M
- Last Round
- $13.0M Venture RoundNov 2024
- Rounds
- 3
About
We're making every therapeutically valuable emotion available on demand in pharmaceutical form. Our Osmanthus platform is an ensemble of AI models that synthesize the world’s largest datasets of psychoactive pharmacology and phenomenology, quantitatively pinpointing the combination of neurotransmitter receptor activity that underlies various emotional as well as cognitive and perceptual states. Our lead program MSD-001 is designed to be rapid-acting and produce heightened emotional and cognitive flexibility without hallucinations. MSD-001 is currently in human trials, and will be the base ingredient for multiple drug combination "emotions in a bottle" such as empathy, awe, clarity, or beauty.
Summary
Mindstate Design Labs is an Artificial Intelligence company based in San Francisco, United States, founded in 2021. It has raised $37.2M in total across 3 rounds, most recently a $13.0M Venture Round round in Nov 2024. Investors include Initialized Capital, Jaan Tallinn and Day One Ventures.
Tech & App Stack
3 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Nov 2024
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Next-gen Medicare Advantage insurance plan with AI-forward medical group delivering quality and s...

Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.

Specialty pharmaceutical company
Biopharmaceutical services company